Mersana Therapeutics

Search
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
      • Our Responsibility
      • Who We Are
      • Our Organization
      • Patient Access and Clinical Trial Practices
      • Our Community
      • Our Planet
    • Partnering
  • Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact
Other, Other, Publications

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance

Immunosynthen, Publications, XMT-2056

XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses

Other, Other, Publications

The Evolving Landscape of Antibody-Drug Conjugates in Gynecologic Cancers

Dolaflexin, Publications, UpRi (XMT-1536)

NaPi2b Expression in High-Grade Serous Ovarian Cancer: Results From Combined Data Sets

Dolaflexin, Publications, UpRi (XMT-1536)

Targeting NaPi2b in ovarian cancer

Dolaflexin, Publications, UpRi (XMT-1536)

Archival vs Fresh Tumor Samples for Assessing the Gene Expression of NaPi2b and Immune-Related Genes in the Phase 1 Study of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

Dolaflexin, Publications, UpRi (XMT-1536)

UP-NEXT (GOG-3049/ENGOT-ov71-NSGO-CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC) in Platinum-Sensitive Recurrent Ovarian Cancer

Dolaflexin, Publications, UpRi (XMT-1536)

UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Antibody-Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer

Dolaflexin, Publications, UpRi (XMT-1536)

UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of the XMT-1536-1 Trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC), in Platinum-Resistant Ovarian Cancer

Dolaflexin, Publications, UpRi (XMT-1536)

Comparison of NaPi2b Expression From Paired Tissue Samples in a Clinical Study of Upifitamab Rilsodotin (UpRi; XMT-1536) Supports a Strategy of Testing in Archival Material

© 2023 Mersana Therapeutics, All Rights Reserved. Privacy Policy | Terms of Use
linkedin icon twitter icon
logo
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
      • Our Responsibility
      • Who We Are
      • Our Organization
      • Patient Access and Clinical Trial Practices
      • Our Community
      • Our Planet
    • Partnering
  • Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact